Zacks Investment Research
08 Jul 2026, 15:40 UTC · 2h ago
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
08 Jul 2026, 15:40 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Xeris Biopharma (XERS) is expected to report a year-over-year quarterly earnings increase of 300% to $0.02 per share. — Triple-digit earnings growth is a strong fundamental catalyst for stock price appreciation.
+0.60Xeris Biopharma (XERS) revenues for the upcoming quarter are projected to increase 26.8% year-over-year to $90.73 million. — Consistent double-digit revenue growth supports the sustainability of the company's growth trajectory.
+0.40Xeris Biopharma (XERS) shares rose 6.8% in the last session on above-average volume, contributing to a 34.1% gain over four weeks. — Strong price action on high volume indicates positive momentum and institutional accumulation.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
The consensus EPS estimate for Xeris Biopharma has remained unchanged over the last 30 days. — A lack of positive earnings revisions often suggests the recent price jump may lack further fundamental support.
Which stocks this story touches
Shares rose 6.8% on strong volume, showing growth in drug portfolios and a projected 300% year-over-year earnings increase.
The stock closed the last trading session 3.4% lower.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
